Theravance Biopharma Presents New Data on VIBATIV
Theravance Biopharma reported new data from multiple studies of VIBATIV (telavancin), the Company’s proprietary FDA-approved antibiotic, at ASM Microbe 2017. Study results highlighted greater in vitro potency for VIBATIV against difficult-to-treat Staphylococcus aureus
) pathogens, including methicillin-resistant Staphylococcus aureus
(MRSA) and those considered to be multidrug-resistant (MDR), as compared to other commercialized antibiotics. Frank Pasqualone, Chief Commercial Operations Officer at Theravance Biopharma, said, “In an environment clouded by the challenges of antibiotic resistance, we believe that the in vitro potency of VIBATIV, coupled with its demonstrated bactericidal activity, provides clinicians an important antibiotic treatment option for some of their most challenging cases, where indicated.”
ASM Microbe 2017 Presentations:
Hennepin Life Sciences Presents Pre-Clinical Data on Broad-Spectrum Topical Gel
Hennepin Life Sciences, a clinical-stage biotechnology company, highlighted its pre-clinical data at this year’s ASM Microbe 2017. The data demonstrated that their proprietary broad-spectrum topical gel with bactericidal activity against pathogenic bacteria, eradicates multi-drug resistant urinary tract infection bacteria in vitro and in vivo. Catheter-associated urinary tract infections (CAUTI) account for one of the top four healthcare costs
in the United States.
ASM Microbe 2017 Presentations:
TECHLAB Showcases Its C. DIFF QUIK CHEK COMPLETE
TECHLAB Inc., a leading developer and manufacturer of rapid, non-invasive diagnostic tests for gastrointestinal disease, attended this year’s ASM Microbe 2017 meeting where they showcased the Company’s C. DIFF QUIK CHEK COMPLETE
. It’s the only complete test for Antigen and Toxins A&B on a single device. C. DIFF QUIK CHEK COMPLETE
allows healthcare professionals to treat the right patients and improve infection prevention measures by differentiating colonized carriers from patients with true disease–molecular tests are unable to make this critical distinction which can lead to overdiagnosis, overtreatment, and increased costs.
Norvir Oral Powder Formulation Approved by FDA
The US Food and Drug Administration (FDA) approved an oral powder formulation (100 mg packet) of AbbVie Inc.’s antiviral Norvir (ritonavir) on June 7, 2017. According to information released by the FDA, “This approval provides for the use of Norvir (ritonavir) oral powder (only for >100 mg dose increments) in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection.” Of note is the fact that this oral powder dosage of Norvir is, “free of alcohol and propylene glycol, both of which are present in the currently marketed Norvir oral solution, making it safer for use in the pediatric population.” The complete revised labeling will be available at DailyMed
Ready-to-Use Clindamycin in Saline from Baxter Approved by FDA
Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery announced today that the FDA has approved their ready-to-use clindamycin injection in saline for 3 commonly prescribed formulations (300mg/50mL, 600mg/50mL, 900mg/50mL). According to a press release
put out by Baxter, “clindamycin injection in saline provides an alternative to administer to patients for whom the use of dextrose is contraindicated or undesirable.”
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.